The ROE as of September 2024 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 35.16%

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 35.16%. This represents a change of 340.00% compared to the average of 7.99% of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical ROE (quarterly & annually)

How has TRDA ROE performed in the past?

The mean historical ROE of Entrada Therapeutics, Inc. over the last ten years is 6.57%. The current 35.16% ROE has changed 434.76% with respect to the historical average. Over the past ten years (40 quarters), TRDA's ROE was at its highest in in the December 2020 quarter at 20.90%. The ROE was at its lowest in in the June 2023 quarter at -12.53%.

Entrada Therapeutics, Inc. (TRDA) ROE by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Entrada Therapeutics, Inc. (TRDA) Average ROE

How has TRDA ROE performed in the past?

The current ROE of Entrada Therapeutics, Inc. (TRDA) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Entrada Therapeutics, Inc. (TRDA) ROE vs. Peers

How is TRDA’s ROE compared to its peers?

Entrada Therapeutics, Inc.’s ROE is greater than Molecular Partners AG (-33.08%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Vigil Neuroscience, Inc. (-76.02%), greater than Third Harmonic Bio, Inc. (-6.80%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Rallybio Corporation (-74.08%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Centessa Pharmaceuticals plc (-63.22%), greater than Disc Medicine, Inc. (-23.78%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than PepGen Inc. (-62.74%), greater than Tyra Biosciences, Inc. (-27.13%), greater than Pharvaris N.V. (-36.89%), less than Eliem Therapeutics, Inc. (0%), greater than Genenta Science S.p.A. (-47.03%), greater than Opthea Limited (-50.79%), less than Pardes Biosciences, Inc. (360.05%), greater than null (-54.84%),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.